Hexadecanoic acid, 1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-2-[(1-oxotetradecyl)oxy]ethyl ester (9CI)

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 英文名称: Hexadecanoic acid, 1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-2-[(1-oxotetradecyl)oxy]ethyl ester (9CI)
• 英文别名: [(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-tetradecanoyloxypropan-2-yl] hexadecanoate
• 化学式: C₃₅H₇₀NO₈P
• 分子量: 663.9
• InChiKey: FXNACVVCWBVCGD-MGBGTMOVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  9.2
• 重原子数：
  45
• 可旋转键数：
  37
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  134
• 氢给体数：
  2
• 氢受体数：
  9

文献信息

• Inhalable formulations for sustained release
  申请人：Advanced Inhalation Research, Inc.

  公开号：US20030232019A1

  公开（公告）日：2003-12-18

  The present invention is based, in part, on the unexpected discovery that aerosol particle formulations for pulmonary delivery of a therapeutic, prophylactic or diagnostic agent comprising an asymmetric phospholipid exhibit sustained release and/or sustained action of the agent. In some embodiments, as an alternative to one or more asymmetric phospholipids or in addition to one or more asymmetric phospholipids, the instant particles comprise one or more glycerol fatty acid esters. The present invention is directed to spray dried non-polymeric particles for pulmonary delivery and sustained release of a therapeutic, prophylactic or diagnostic agent and methods for delivery of said particles to the pulmonary system, the particles comprising a therapeutic, prophylactic or diagnostic agent and an asymmetric phospholipid and/or one or more glycerol fatty acid esters. In one embodiment, the particles comprise a combination of phospholipids wherein at least one of the phospholipids is an asymmetric phospholipid. In another embodiment, the particles comprise one or more phospholipids and one or more glycerol fatty acid esters.

  本发明的部分依据是意外发现用于肺部给药的治疗、预防或诊断药剂的气溶胶颗粒制剂包含一种不对称磷脂，该不对称磷脂显示出药剂的持续释放和/或持续作用。在某些实施方案中，作为一种或多种不对称磷脂的替代品，或作为一种或多种不对称磷脂的补充，即时颗粒包含一种或多种甘油脂肪酸酯。本发明涉及用于肺部递送和持续释放治疗剂、预防剂或诊断剂的喷雾干燥非聚合物微粒，以及将所述微粒递送至肺部系统的方法，所述微粒包括治疗剂、预防剂或诊断剂和非对称磷脂和/或一种或多种甘油脂肪酸酯。在一个实施方案中，微粒由磷脂组合而成，其中至少有一种磷脂是不对称磷脂。在另一个实施方案中，颗粒由一种或多种磷脂和一种或多种甘油脂肪酸酯组成。